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Abstract 
Genome editing allows for the precise manipulation of DNA sequences in a cell making this technology essential for 
understanding gene function. CRISPR/Cas9 is a targeted genome-editing platform derived from bacterial adaptive 
immune system and has been repurposed into a genome-editing tool. The RNA-guided DNA endonuclease, Cas9 can 
be easily programmed to target new sites by altering its guide RNA sequence, making this technology easier, more 
efficient, scalable and an indispensable tool in biological research. This technology has helped genetically engineer 
animal models to understand disease mechanisms and elucidate molecular details that can be exploited for improved 
therapeutic outcomes. In this review, we describe the CRISPR–Cas9 gene-editing mechanism, CRISPR-screening 
methods, therapeutic targeting of CRISPR in animal models and in cancer immunotherapy. We also discuss the ongo-
ing clinical trials using this tool, limitations of this tool that might impede the clinical applicability of CRISPR–Cas9 and 
future directions for developing effective CRISPR–Cas9 delivery systems that may improve cancer therapeutics.
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Introduction
Cancer is the second leading cause of mortality world-
wide accounting for 8.8 million deaths in 2015 (WHO). 
Globally, 1 out of 6 death is caused by cancer (WHO). 
The cost associated with cancer is significant and increas-
ing with an estimated annual cost of approximately USD 
1.16 trillion in 2010 [1]. The socio-economic burden and 
mortality associated with cancer is largely due the gaps in 
our understanding of the molecular details of the disease 
and lack of cost effective treatment regimens. Adding to 
this complexity are the issues of differential mutational 
load, tumor heterogeneity and therapeutic resistance 
that determine clinical outcomes for targeted cancer 
therapies. The gene editing technology, CRISPR/Cas9 
has allowed us to better understand how a gene product 
contributes to development and disease in an organism. 
In this review, we discuss developing effective CRISPR–
Cas9 delivery systems for improved cancer treatment.
CRISPR/Cas system: a gene‑editing tool
Understanding a gene function relies on controlled alter-
ation of its DNA sequence in a cell. Although, several 
editing enzymes like zinc finger nucleases (ZFNs), tran-
scription activator-like effector nucleases (TALENs) and 
homing meganucleases are effective they require reengi-
neering the enzyme for each target sequence [2–4]. On 
the other hand, homologous recombination (HR) based 
genetic engineering methods have lower editing effi-
ciency and thereby warrant screening a larger sample 
size [5]. The clustered regularly interspaced short palin-
dromic repeats (CRISPR)/CRISPR-associated nuclease 9 
(Cas9) is a technology which is scalable, affordable and 
easy to engineer [6, 7]. The CRISPR/Cas9 system was first 
observed as microbial defense immunity against invading 
viruses or other genetic elements [8, 9]. This natural sys-
tem was further adapted for genome editing by program-
ming site-specific DNA double strand breaks (DSBs) and 
editing the mammalian genome with high precision [10].
Cas9 generates DSBs at a target genetic locus like ZFNs 
[11–14] and TALENs [15–21]. The advantage of Cas9 
editing is that its nuclease function is guided either by 
a natural dual-RNA complex or a chimeric single-guide 
Open Access
Cancer Cell International
*Correspondence:  snandi@cshl.edu; bhattacharjee@cshl.edu 
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
Page 2 of 10Ghosh et al. Cancer Cell Int           (2019) 19:12 
RNA (sgRNA) that recognizes target sequences via Wat-
son–Crick base pairing [22, 23]. The DSB generated by 
the nuclease action of Cas9 activates the cellular DNA 
damage response that is critical for the maintenance of 
genome stability [24]. Organisms have evolved with two 
major pathways for the repair of DSBs in mammalian 
cells: the non-homologous end joining (NHEJ) path-
way, which is a template-independent error prone path-
way of DNA double strand break repair (DSBR) and the 
homology directed repair (HDR) pathway which relies on 
extensive homology for DSBR and is considered a error 
free pathway [25–29]. Repair by NHEJ introduces inser-
tion/deletion (Indel) mutations and larger deletions in 
the genome [30–32]. In contrast HDR, introduces a site-
specific mutations at a target locus [33] (Fig. 1).
There is an increasing effort in re-engineering the 
CRISPR/Cas system in order to meet three major aims: 
(i) decreasing size of the Cas9 nuclease (ii) increasing its 
fidelity and (iii) improving Cas targeting efficiency [34].
Three types (I–III) of CRISPR systems have been 
identified thus far, each system contains (i) cluster of 
CRISPR-associated (Cas9) genes, (ii) non-coding RNAs 
and (iii) an array of repetitive elements (direct repeats) 
[35]. The direct repeats interspersed by protospacers 
(short variable sequences derived from the exogenous 
DNA targets) forms the CRISPR RNA (crRNA) array 
[35]. Each CRISPR system contains a protospacer adja-
cent motif (PAM) within the DNA target [8, 36, 37]. 
The CRISPR–Cas system is divided into two classes: 
class 1 contains multiple Cas proteins, and class 2 con-
tains a single Cas protein [38–40] (Table 1). Class 1 sys-
tem is composed of types I, III and IV and the class 2 
CRISPR/Cas system is further divided into types II, V, 
VI [41]. The type I systems use Cas3 enzyme, type II 
systems use Cas9, type III systems use Cas10 enzyme, 
type IV systems use Csf1 protein, type V systems use 
Cpf1, C2c1 or C2c3, and type VI use protein Cas13a 
[42]. The best-characterized CRISPR system is the type 
II CRISPR system; it consists of the Cas9 nuclease, 
crRNA array and an additional trans-activating crRNA 
(tracrRNA) [22, 23, 43]. The crRNA and tracrRNA are 
fused to form a chimeric sgRNA. By altering this 20nt 
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Fig. 1 Schematic of CRISPR–Cas9-mediated genome editing. The Streptococcus pyogenes derived CRISPR–Cas9 RNA-programmable DNA 
endonuclease is targeted to a DNA sequence via a single guide RNA (sgRNA) sequence, which base-pairs with a 20-nt DNA sequence upstream of 
the protospacer-associated motif (PAM), resulting in a 3-bp double-strand break (DSB) upstream of the NGG. The resulting DSBs are subsequently 
repaired either by non-homologous end joining (NHEJ) or by homology-directed repair (HDR). Repair via the error-prone NHEJ pathway, frequently 
leads to insertion or deletion mutations (Indels) that can lead to genome instability. Alternatively, in the presence of an exogenous donor DNA 
template, the DSB can be repaired via the error-free HDR pathway, which can engineer precise DNA modifications
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guide sequence within the sgRNA, Cas9 can be redi-
rected to any target sequence in the vicinity of the PAM 
sequence, typically NGG [43]. The type-II Cas9 effec-
tor nucleases are best characterized and are used for 
genome engineering technologies [44, 45].
A new Cas effector nuclease Cpf1 (also known as 
Cas12a) has been recently identified [46]. It is a type 
V effector and is guided by crRNA rather than crRNA 
and trancrRNA dual guide system used by Cas9 [46, 
47]. Also, Cpf1 recognizes T-rich PAM sequences adja-
cent to the target DNA unlike Cas9, which recognizes 
G-rich PAM [43, 48–50]. Furthermore, Cpf1 introduces 
a staggered DSB with a 4 or 5-nt overhang at the PAM-
distal region unlike Cas9, which generates blunt ends at 
its PAM-proximal region [23]. Cpf1 shows better target 
specificity than Cas9 [51, 52] and can also process its 
own crRNA array to generate mature crRNAs [53].
One screening study using 15 orthologous has lead 
to the identification of another nuclease, Cas13a from 
Leptotrichia wadei (LwaCas13a) [54]. LwaCas13a 
has shown to be effective in targeted knockdown of 
reporter or endogenous targets to similar levels as RNA 
interference but with greater specificity [54].
Biochemical and genetic studies demonstrate effector 
nuclease Cas13b, which can process its own CRISPR 
array with short and long repeats, has RNase activ-
ity and can cleave target RNA [55]. It also has a proto-
spacer-flanking sequence required for RNA targeting 
[55]. The associated proteins Csx27 represses, whereas 
Csx28 enhances the Cas513b mediated RNA interfer-
ence [55].
Mutating both nuclease domains of Cas9 renders 
the protein catalytically dead (dCas9). dCas9 can bind 
the target DNA without cleaving it [56, 57]. The dCas9 
fusion protein [Cas9-KRAB] with Kruppel associated 
box (KRAB) domain of Kox1 protein recruits chro-
matin modifying factors and silences gene expression 
[57]. dCas9 can also be used for gene activation, this 
approach is known as CRISPR activator (CRISPRa); 
dCas9 can also mediate reversible CRISPR interference 
(CRISPRi) [57–60]. Gene editing can be modulated by 
combining CRISPRi and CRISPRa [61].
CRISPR‑screening
High throughput gain-of-function (GOF) or loss-of-
function (LOF) screening is important for identify-
ing new factors in a pathway or interactions between 
components of a pathway [62]. Limitations of the con-
ventional short hairpin RNA (shRNA) mediated gene 
silencing include off target effects, high false positive 
rates, high false negative rates and lack of high through-
put data due to high costs and large library sizes [63–66]. 
On other hand, cDNA and ORF mediated GOF screens 
are high throughput, but time consuming and cannot be 
used for genome-wide studies due to technical limita-
tions [67]. sgRNA mediated screens are most useful for 
high throughput screening because the short and uni-
form sgRNA size allows for targeting the whole genome 
[68, 69]. In cancer, CRISPR screens have helped identify 
genes involved in drug resistance [60, 70–72], synergis-
tic and synthetic lethal interactions [73, 74], regulators of 
PD-L1 expression [75] and others [76, 77].
Loss‑of‑function CRISPR library screen
CRISPR knock out and CRISPRi has been successfully 
used to screen large sgRNA libraries. This approach has 
identified essential cancer genes implicated in cell sign-
aling, differentiation, survival and regulatory processes 
[76–78]. The best examples of the success of this screen-
ing method include the identification of the role of BCR 
and ABL as lethal hits in chronic myelogenous leukemia 
(CML) cell line KBM7, KRAS and PIK3CA and as lethal 
hits in colorectal cancer cell lines DLD-1 and HCT116 
[68, 76]. KRAS-mutated DLD-1 cell line showed high 
dependency on mitochondrial function [76]. Burkitt’s 
lymphoma cell line Raji showed dependency on the 
DEAD-box helicase DDX3Y located on the Y-chromo-
some [77].
On the other hand, positive selection screening with 
LOF CRISPR libraries have provide crucial information 
Table 1 Cas9 proteins and their function in CRISPR editing
Cas protein CRISPR system Guide RNA Nuclease activity Recognition sequence 
on target
Reference
Cas9 Type II crRNA + transcrRNA Yes G-rich PAM [49, 50]
Cpf1 Type V crRNA Yes G-rich PAM [46]
Cas13a Type VI-A crRNA + transcrRNA Yes Except G-rich [54]
dCas9 Type II crRNA + transcrRNA No G-rich PAM [140]
Cas3 Type I crRNA Yes T-rich PAM [141, 142]
Cas10/Csm1 Type III crRNA Yes AT-rich PAM [143, 144]
dCas13a Type VI-A crRNA + transcrRNA Yes Except G-rich [145]
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regarding drug resistance [68, 69]. A drug resistant screen 
performed on KBM7 cells against antimetabolite 6-thi-
ogranine identified genes involved in DNA mismatch 
repair [79]. Another screen used DNA topoisomerase 
II (TOP2A) poison etoposide to identify TOP2A gene 
and cyclin-dependent kinase 6 (CDK6) in promyelo-
cytic leukemia (PML) cell line HL60 [68]. A drug resist-
ance screen with therapeutic RAF inhibitor vemurafenib 
in melanoma cell line A375 showed involvement of well 
characterized genes like NF1 and MED12 as well as novel 
hits like NF2, CUL3, TADA2B and TADA1 [69].
Gain‑of‑function CRISPR library screen
The GOF screens aim at identifying positive and nega-
tive regulators of cancer proliferation pathways and use 
CRISPRa as the screening method [60]. CRISPRa medi-
ated activation of tumor suppressors and lineage differen-
tiation genes in K562; a CML cell line showed inhibition 
of cell proliferation [80]. This suggests a transient inacti-
vation of the tumor suppressor genes during cell prolif-
eration. CRISPRa mediated activation of drug resistance 
genes for the BRAF inhibitor vemurafenib in A375 cells 
suggests a mechanism of bypassing BRAF inhibition by 
either reactivating the MAPK pathway through BRAF 
independent mechanisms or MAPK-independent parallel 
pathways [60].
In‑vivo CRISPR screening
While in vitro screens answer some important questions 
about the intrinsic properties of cancer cells and poten-
tial therapeutic opportunities, they have failed to answer 
some key questions [81]. For example, how does the com-
plex interaction between the cell and its microenviron-
ment influence tumor behavior? In vivo CRISPR screens 
are performed to answer these questions. The first in vivo 
CRISPR screen was designed to investigate the role of 
annotated genes in tumor growth and metastasis when 
mutagenized [82].
Transplant based in vivo CRISPR screens
In vivo CRISPR screen is a two-step workflow: (i) intro-
duction of sgRNA library to cells in culture systems 
and (ii) transplantation into mice to assess phenotypes 
in  vivo [83]. The cells are sequenced after selection to 
identify reduced and/or depleted sgRNAs [84]. Several 
in vivo CRISPR screens have lead to the identification of 
tumor suppressors, oncogenes, synthetically lethal genes, 
metastasis and regulators of cancer immunotherapy in 
co-culture systems and transplant tumor models [82, 84–
89]. However, transplant based in  vivo CRISPR screens 
have certain downsides; for example: (i) large number of 
cancer cells in mice do not mimic in vivo condition, (ii) 
sub-cutaneous transplantation does not reflect the same 
result as orthotropic transplantation to relevant organ, 
and (iii) grafting in immunodeficient mice does not allow 
for the study of cancer-immune interactions.
Direct in vivo CRISPR screen
Direct in vivo CRISPR screens overcome some of limita-
tions of transplant based in vivo CRISPR screens because 
in  vivo mutagenesis is performed directly at the organ 
site [90, 91]. Multiplexed mutagenesis in hepatocytes 
of Cas9 mice has been reported when sgRNA contain-
ing plasmids are injected into tail vein [92]. A lentivirus 
mediated sgRNA delivery into lung intratrachea leads to 
mutagenesis in Cas9 expressing lung epithelial cells [93]. 
Furthermore, direct mutagenesis in mouse brain is made 
possible by using adenoassociated viruses (AAVs) [94]. 
A CRISPR/Cas9 mediated multiplexed-mutagenesis has 
been recently performed to induce hepatocellular carci-
noma (HCC) and intrahepatic cholangiocarcinoma (ICC) 
showing that this approach is suitable for both recessive 
genetic screening and high-throughput cancer gene vali-
dation in mice [95]. An AAV sgRNA library containing 
280 sgRNAs targeting 56 genes delivered into mouse 
brain induced glioblastoma mimicking the pathology 
of the human disease [90, 96]. However, direct in  vivo 
CRISPR screening approaches also have its own limita-
tions which include (i) unknown cell–cell interactions in 
the host tissue, (ii) low viral transduction efficiency, and 
(iii) immune rejection [90].
Therapeutic targeting of CRISPR in cancer 
and animal models
Along with high throughput screening, CRISPR/Cas9 
mediated editing has been used to generate disease mod-
els which can be used for preclinical validation of onco-
genes, drug targets and drug resistance in cancer (Fig. 2).
Cell lines
CRISPR/Cas9 and TALEN mediated knock-in of induc-
ible degron tags (Degron KI) allow for the specific, induc-
ible and allele specific inhibition of protein function [97]. 
This approach has provided a better understanding of 
the pharmacological EZH2 and PI3Kα inhibitors in can-
cer cell lines [97]. The Degron-KI system has also helped 
identify the link between putative oncogene SF3B1 hot-
spot mutations and splicing alterations [97]. CRISPR/
Cas9 has been used to study genomic rearrangements 
including CD74-ROS1 translocation and EML4-ALK 
and KIF5B-RET inversion events, which are drivers of 
lung cancer [98]. CRSIPR/Cas9 mediated genome engi-
neering has also been used to generate cell lines carrying 
chromosomal translocations which provide information 
about early events in the pathology of acute myeloid leu-
kemia (AML) and Ewing’s sarcoma [99]. CRSIPR/Cas9 
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mediated genome engineering has also been used to 
generate cell lines, followed by a second screen in  vivo 
in order to identify novel targets for AML therapy [100]. 
CRISPR mediated editing of the HER2 gene in breast 
cancer cell lines revealed a novel mechanism of anti-can-
cer effects of HER2 targeting by CRISPR/Cas9, an alter-
native to clinical drug Herceptin [101].
Organoid cancer models
CRISPR/Cas9 mediated editing has been used to intro-
duce multiple mutations in human intestinal epithelium 
derived organoids [102]. Isogenic organoids with muta-
tions in tumor suppressor genes APC, SMAD4, TP53 
and oncogenes KRAS and/or PIK3Ca are selected and 
implanted in mice where they form tumors and success-
fully mimic colon cancer in  vitro [103]. CRISPR/Cas9 
mediated deletion of DNA repair genes in colon orga-
noids has been successfully modeled mismatch repair 
deficient colorectal cancer [104]. CRISPR–Cas9-based 
genome editing of PDAC driver genes in pancreatic 
tumor organoids reveals Wnt niche independence during 
tumorigenesis [105].
Mouse models
CRISPR/Cas9 driven mutagenesis has been used to 
mutate 5 genes (Tet1, 2, 3, Sry, Uty-8 alleles) in mouse 
ES cells in a single step, which reduces the complex-
ity of generating multi-gene cancer models [106]. Tet1 
and Tet2 gene mutations were generated with 80% effi-
ciency by coinjecting Cas9 mRNA and sgRNAs directly 
into the mice zygote [106]. Cre-dependent somatic 
activation of oncogenic Kras (G12D) in combination 
of CRISPR/Cas9 mediated genome editing led to the 
generation of lung adenocarcinomas in mouse models 
which enabled the functional characterization of puta-
tive cancer genes [93]. A hydrodynamic injection of 
CRISPR plasmid DNA expressing Cas9 and sgRNAs 
against tumor suppressor genes Pten and p53 alone or 
in combination directly into the mouse liver induced 
tumor and is being used as a cancer model [92]. A point 
mutation in Ctnnb1 gene in the liver was introduced by 
hydrodynamic injection of Cas9 plasmid and Ctnnb1 
sgRNA together with a mutant Ctnnb1 HDR template 
[92]. The intratracheal delivery of adenovirus or lentivi-
ral vector with Cas9 and sgRNA for Em14 and Alk led 
to tumor formation in mouse lungs [107, 108].
Cre dependent Cas9 knock in mouse was generated 
and using these mice, KRAS, p53 and LKB1 gene muta-
tions were modeled for lung adenocarcinoma [109]. 
An intraductal injection of lentivirus-encoding Cas9 
was used to generate invasive lobular breast carcinoma 
(ILC) with conditional alleles of Cdh1 gene, encoding 
E-cadherin [110, 111].
Pre-clinical trials
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Fig. 2 Application of CRISPR–Cas9-mediated genome engineering in studying preclinical models as well as in editing clinical targets
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CRISPR in cancer immunotherapy
Immunotherapy is increasingly becoming the corner-
stone of current day cancer treatment [112]. The use of 
immune checkpoint inhibitors in immunotherapy has 
been shown to reverse dysfunctional or exhausted T-cells 
and thereby improve efficacy in solid and hematologi-
cal cancers [113, 114]. A second line of immunotherapy 
involves the use of genetically engineered T-cells such as 
the chimeric antigen receptor (CAR-T) [115] (Fig. 2).
CRISPR/Cas‑9 in CAR‑T
In this approach, patient derived T-cells are genetically 
modified in  vitro and then introduced back in patients 
in order to improve the efficacy of targeted T-cells kill-
ing [116–120]. CAR has an intracellular chimeric signal-
ing domain, which helps activate T-cells, and also has a 
single-chain variable fragment that specifically recog-
nizes tumor antigens [121, 122]. So far, CAR-T cell ther-
apy has been most successful in targeting CD19 surface 
marker in B cell malignancies due to its expression pat-
tern in this cellular subtype [123, 124]. Other limitation 
of CAR-T cell therapy includes, (i) generation of patient 
derived CAR-T cells (autologous CAR-T cells) is costly, 
(ii) time consuming and (iii) technically challenging 
[125]. In order to overcome these problems, allogeneic 
universal T-cells are derived from healthy donors, which 
do not contain endogenous TCR and HLA class I to elim-
inate graft-versus-host rejection [126]. CRISPR/Cas9 has 
been used to disrupt multiple loci to generate universal 
CAR-T donor cells [127]. The Fas receptor (CD95), upon 
combining with its ligand, leads to induction of T-cells 
apoptosis and CAR-T function. Therefore, Fas knockout 
CAR-T cells generated by CRISPR/Cas-9 show improved 
tumor cell death and prolonged survival in mice [127]. 
Furthermore, CRISPR/Cas9 mediated generation of CAR 
into the T-cell receptor alpha constant (TRAC) locus 
showed an uniform CAR expression in T-cell, increased 
T-cell efficiency and retention in mouse model of AML 
[128].
CRISPR/Cas9 in PD‑1 and CTLA‑4
The CRISPR/Cas9 based editing has been used to disrupt 
T-cell surface receptors, such as programmed cell death 
protein 1 (PD-1) and cytotoxic T lymphocyte-associ-
ated protein 4 (CTLA-4) in order to increase efficiency 
of T-cell based immunotherapy [127, 129, 130]. The first 
clinical trial used CRISPR/Cas9 mediated PD-1 knockout 
T-cells in lung cancer patients [131]. Ongoing clinical tri-
als include PD-1 knockout autologous T-cells in prostate 
cancer (NCT02867345), bladder cancer (NCT02863913) 
and renal cell carcinoma (NCT02867332). CRISPR/Cas-9 
mediated simultaneous knockout of 4 loci of PD-1 and 
CTLA-4 have been successful in generating allogeneic 
universal T-donor cells [127]. CRISPR/Cas9 mediated 
generation of lymphocyte activating gene-3 (LAG-3) 
knockout CAR-T cells shows better specificity and anti-
tumor potential in xenograft mouse models [132].
CRISPR/Cas‑9 and PTPN2
Immunotherapies with PD-1 checkpoint inhibitors 
do not work for majority of patients. This necessitates 
identifying alternative targets for immunotherapy. A 
CRISPR–Cas9 based in  vivo screen identified protein 
tyrosine phosphatase non-receptor type 2 (PTPN2) as 
a novel immunotherapy target in cancer [85]. The study 
showed enhanced efficacy of immunotherapy by deletion 
of PTPN2 via interferon gamma mediated pathway [81].
Clinical trials
CRISPR/Cas9 mediated cancer gene editing was 
first tested in patients with aggressive lung cancer 
(NCT02793856). In this trial, the immune cells from 
recipient blood was removed followed by ex  vivo 
CRISPR/Cas9 editing thereby disabling PD-1 protein 
[131]. In  vivo CRISPR/Cas9 genome editing is ongoing 
and shows promise but is yet to be tested in clinical trails. 
A new clinical trail (NCT03057912) proposes to use a 
combination of TALENs and CRISPR/Cas9 in the treat-
ment of HPV-related cervical neoplasma by targeting 
HPV16 and HPV18 E6/E7 DNA; this approach promises 
to reduce off-target effects. Table  2 summarizes a com-
prehensive list of ongoing CRISPR/Cas9 clinical trials.
Challenges of CRISPR/Cas9 in therapeutic targeting
CRISPR/Cas9 mediated in vitro and in vivo gene editing 
is an excellent tool for studying disease mutations. How-
ever, it is not error-free and the system fails about 15% of 
the time [133–135]. Below we summarize the major chal-
lenges of CRISPR/Cas9 mediated cancer therapy.
Cas9‑DSB complex
Recent studies have shown that the persistent binding 
of Cas9 to DSBs blocks the access of repair proteins to 
the break site, thereby reducing repair efficiency [136]. 
This makes Cas9-DSB complex the rate-limiting step 
during genome editing in vivo. Studies have also shown 
that template bound Cas9 can be dislodged by the trans-
locating RNA polymerase only when the polymerase 
approaches the DSB from a particular direction [129].
Immunity against Cas9 protein
A potential explanation for the failure of CRISPR/
Cas9 mediated editing in  vivo arises from the humoral 
and cell-mediated adaptive immune response to bac-
terial Cas9 [137]. A recent study aimed at finding the 
Page 7 of 10Ghosh et al. Cancer Cell Int           (2019) 19:12 
presence of pre-existing adaptive immune response to 
the Cas9 homologs: SaCas9 (S. aureus homolog of Cas9) 
and SpCas9 (S. pyogenes homolog of Cas9). This study 
reported the presence of 79% of donors stained posi-
tive for SaCas9 and 65% of donors stained positive for 
SpCas9. Also, in peripheral human blood, 46% donor 
stained for SaCas9 T-cells [137].
On‑target effects of CRISPR/Cas9 editing
Using long-read sequencing and long-range PCR geno-
typing, a recent study revealed that repair of DNA breaks 
introduced by Cas9 result in large deletions and genetic 
alterations [138]. The authors also observed that both 
the lesions and the resulting crossover event occur far 
from the cut site [138]. This study brings forth the issue 
of CRISPR/Cas9 mediated on-target damage, which 
may lead to activation of dormant oncogenes, inactiva-
tion of tumor-suppressors genes and other disease caus-
ing genes [138]. The on target effects of CRISPR/Cas9 
can be avoided by sequencing a few clones and looking 
for unwanted genomic alteration before introducing the 
clones back for expansion [138].
Off‑target effects of CRISPR/Cas9 editing
Although, the targeting efficiency of Cas9 is controlled 
by the first 20-nucleotide of the sgRNA, several studies 
have reported the potential off-target effects that gives 
rise to chromosomal rearrangements and can induce 
mutations. These off-target effects include incorporation 
of DNA mismatches in PAM-distal part of the sgRNA 
sequence [32, 58, 139–141]. Some strategies to avoid 
or at least minimize off-target effects of CRISPR/Cas9 
editing include (i) choosing unique target sites that lack 
homology to any other region of the genome, (ii) modi-
fying Cas9 by replacing wild type Cas9 with dCas9, (iii) 
fusing dCas9 with FokI nuclease (fCas9) which has higher 
sequence targeting specificity, (iv) modifying sgRNA by 
truncating the 3′end of sgRNA, and (v) reducing the con-
centration of Cas9-sgRNA delivered to cells [133].
Future direction
CRISPR-based technologies have turned out be indis-
pensable for scientific advancements. This is due to its 
wide applicability in both basic research in understand-
ing fundamentals questions about how genes work as 
well as in the development of biotherapies for complex 
diseases like cancer. However, there are still several chal-
lenges associated with this technology that need to be 
addressed. For instance, the large size of Cas9 makes it 
difficult to package the protein in low immunogenic 
AAV vectors used in vivo and in vitro gene delivery. Also, 
Cas9 from S. aureus and S. pyogenes has been shown to 
cause infectious diseases in humans. One possible strat-
egy to overcome this issue is to redesign Cas9 or use a 
different bacterial protein that is able to escape the host 
immune response. Intellia Therapeutics has developed a 
lipid-nanoparticle based CRISPR/Cas9 delivery system, 
which is enough to edit genes in rodents and non-human 
primates. There are also ethical concerns about this tech-
nology. With the reported birth of the “CRISPR babies” 
in November 2018, scientists have to collectively respond 
to the challenge of CRISPR potentially ushering in the 
era of genetic inequality and its long-term ramifications. 
Although these challenges persist, CRISPR-based tech-
nologies hold immense potential and are a great addi-
tion to the genome editing toolbox for the development 
of biotherapies that can improve patient outcomes in the 
future.
Table 2 Clinical trials studies on CRISPR/Cas9 in different type of cancer
Target Cancer type Stage of testing Reference
CISH gene within tumor-infiltrating lymphocytes inacti-
vated by CRISPR/Cas9
Metastatic gastrointestinal epithelial cancer Phase II NCT03538613
PD1 knockout engineered T- cells Advanced esophageal cancer Phase II NCT03081715
PD-1 knockout EBV-CTLs Advanced stage Epstein–Barr virus (EBV) associated 
malignancies
Phase II NCT03044743
Gene-disrupted allogeneic CD19-directed BBζ CAR-T 
cells (UCART019)
Relapsed or refractory CD19+ leukemia and lymphoma Phase II NCT03166878
Dual Specificity CD19 and CD20 or CD22 CAR-T Cell 
Immunotherapy
Relapsed or refractory leukemia and lymphoma Phase II NCT03398967
PD-1 and TCR gene-knocked out mesothelin-directed 
CAR-T cells
Mesothelin positive multiple solid tumors Phase I NCT03545815
PD-1 knockout engineered T Cells Metastatic non-small cell lung cancer Phase I NCT02793856
NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited 
T-cells (NYCE T-cells)
Multiple myeloma melanoma synovial sarcoma myxoid/
round cell liposarcoma
Phase I NCT03399448
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